Kentucky Board of Pharmacy Collaborative Practice Agreement

The ability of pharmacists to provide care under a protocol approved by the prescriber is different from that provided for in a collaborative care agreement, as protocol-based care may be provided to anyone who requests treatment and meets the criteria for care described in the protocol authorized by the board. On the other hand, pharmacists are only authorized to take care of patients under a collaborative agreement on the recommendation of the prescribing physician. Collaborative care arrangements are therefore better used for chronic care management, which requires ongoing follow-up communication with the referring prescribing physician. Protocol-based care in pharmacies can eliminate potential delays in treatment, as anyone who visits a pharmacy who needs acute care under the conditions approved by the prescription and who meets the care criteria described in the specific protocol can be treated. These efforts were led by the Advancing Pharmacy Practice in Kentucky Coalition (APPKC), an advocacy group comprised of key pharmacy stakeholders in Kentucky, including the Kentucky Pharmacists Association, the Kentucky Society of Health System Pharmacists, the Kentucky Board of Pharmacy, the American Pharmacy Services Corporation, Sullivan University College of Pharmacy, and the University of Pharmacy`s Center for the Advancement of Pharmacy. Kentucky College of Pharmacy. Practice, work together to advance pharmacy practice in Kentucky and the country. The culmination of nearly two years of joint effort was reached last December when the Kentucky Legislature`s Acting Joint Committee on Health, Welfare and Family Services approved Ordinance 201 KAR 2:380, protocols authorized by the board. 3. Directive 315.121 (5) provides that a pharmacist, pharmacist, licensee or licensee whose authorization has been suspended, restricted, restricted or revoked under this Division has the opportunity to demonstrate, at reasonable intervals, that he or she can resume the practice of the competent officer or the provision of medical equipment or services with adequate competence and safety to patients. (d) a person participating in a residency or scholarship program approved by the Board of Directors for internship credit; (b) The disclosure or disclosure of information or the nature of professional services provided to unauthorized persons without the express consent of the patient or without the order or direction of a court. In addition to members, inspectors or representatives of the Board of Directors, the following persons are considered qualified persons: (12) The Kentucky Board of Pharmacy may waive the licensing requirements set forth in this Chapter for a non-governmental pharmacy operating solely in the Commonwealth of Kentucky in limited transactions. (k) the establishment of an advisory committee to advise the committee, at the discretion of the committee, on administrative provisions and other matters relating to the regulation of pharmacists, pharmacists, pharmacists, pharmacists, pharmacies, dismemberment distribution, manufacture of drugs and medical devices and services for family physicians.

The Board of Directors is composed of nine (9) members elected by the Board of Directors for a maximum of four (4) years. No member may be a member of the Board of Directors for more than eight (8) years. The Council consists of nine (9) persons who generally represent the profession of pharmacist, the profession of medical equipment and domestic services and the public. Members will be selected by the Board of Directors from a list of qualified candidates submitted by the Association, the Society or other interested parties; (g) the purchase or purchase of a medicinal product for personal use by a health care establishment or pharmacy that is a member of a group purchasing organisation or by health care establishments or pharmacies that are members of the group organisation; 1. The members of the board of directors, their representatives and employees shall be exempt from any legal action in the case of a civil or criminal act resulting from an official act or an act performed in good faith. (4) a “collaborative care agreement” means a written agreement between an identified physician and a specifically identified pharmacist, in which the physician describes a cooperative management plan for the drug-related health needs of a specifically identified patient that falls within the physician`s legal scope. The agreement is limited to the specifications of the drug regimen to be transferred and to all the tests that must necessarily be indicated in its provisions; the conditions for initiating, continuing or stopping drug treatment; instructions for monitoring treatment and defined conditions justifying changes in dose, dosing regimen, dosage form or route of administration; KRS315.135 Registration as a pharmacy technician is required to support pharmacy in practice – exceptions. KRS 315.138 Renewal of registration as a pharmacy technician – issuance of certificate of accreditation. 1.

A wholesaler shall be authorized by the board of directors in accordance with this Section before engaging in the wholesale of medicinal products prescribed for medical purposes in the Commonwealth. The regulation was published in response to the 2016 Law amending krS 315.010 (25) in order to define valid orders issued on the basis of protocols authorised by the Commission. This act created the conditions for the Kentucky Board of Pharmacy to establish procedures for council-authorized protocols that allow pharmacists acting under the direction of a prescribing physician to provide mutually agreed services, as described in a specific care protocol. Protocols for tuberculosis skin testing, opioid use disorders and self-sufficiency in diabetes screening equipment were established on July 17. January 2018 approved by the Board of Directors and will soon be available on the Board`s website. Protocols for other authorized conditions are being developed. In Kentucky, as in many states, access to care is an important issue. The Health Resources and Service Administration`s Health Workforce Analysis estimates that Kentucky is expected to have a nearly 30 percent deficit in basic care adequacy by 2025.

Plans to develop education and training to prepare pharmacists to provide protocol-based care for the 12 approved conditions are underway. The regulation outlines the procedures that must be in place for a pharmacist to begin dispensing uncontrolled or over-the-counter drugs and related professional services. There must be a protocol approved by the prescriber based on current clinical guidelines, meeting the minimum requirements, and approved by the pharmacy board. In addition, the regulation states that pharmacists must document that they have received training and further training in the area of the protocol prior to the start of treatment under the protocol. As with the administration of naloxone, medicinal products dispensed in accordance with the protocol should be documented in the administration system in accordance with 201 KAR 2:170. Pharmacists have a long history of working with physicians and other prescribing physicians to provide immunization services through the protocol and, more recently, with physicians to initiate the administration of naloxone as part of the protocol. With the implementation of this regulation, the Kentucky Board of Pharmacy is now able to review and approve protocols for 13 authorized conditions. And there is evidence that pharmacists who provide direct patient care based on the protocol can improve both patient health and public health. Many organizations, including the Centers for Disease Control (CDC), the Centers for Medicare and Medicaid Services (CMS), and the National Governor`s Association, have recognized the value that pharmacist-provided care can bring to the health of our country. According to the CDC, Kentucky has the unenviable distinction of having the highest overall rate of lung cancer incidence and death in the country. Smoking is the most common cause of lung cancer and is associated with 80-90% of all lung cancers.

In response to these urgent health problems in Kentucky, the first protocol authorized by the Council was released on June 20. In December 2017, it approved the Tobacco Control Treatment Protocol, which sets out the criteria and procedures for pharmacists to initiate the provision of smoking cessation therapies to people with a smoking disorder. .

Comments are closed.